Sanders: GOP blocked 'Trump proposal' to lower drug prices
© Getty
The Independent Vermont senator tried to get unanimous consent to amend the 21st Century Cures Act, which is expected to pass the Senate on Wednesday, to allow the importing of prescription drugs from other countries and for Medicare to negotiate drug prices. 
He linked his amendment to President-elect Donald TrumpDonald John TrumpBiden slams Trump over golf gif hitting Clinton Trump Jr. declines further Secret Service protection: report Report: Mueller warned Manafort to expect an indictment MORE's comments on the campaign trail about prescription drug prices. 
"During this campaign ... Trump promised among other things to lower the prices of prescription drugs," Sanders said from the Senate floor. 
"I am quite confident that all of my Republican colleagues will support an amendment in my hands that will do exactly what Trump said he would accomplish as president," he added. 
But Sen. Roy BluntRoy Dean BluntTop Senate Dem: We're going forward with understanding we can work with White House on DACA Sunday shows preview: Trump officials gear up for UN assembly Air Force One is Trump’s new boardroom MORE (R-Mo.), a member of GOP leadership, blocked the former Democratic presidential candidate's move, arguing it would threaten the passage of the medical cures legislation. 
"The sure way for this bill not to pass in this Congress is to do something that changes the subject," he said. 
He added that he was "particularly glad" to see Sanders agree with a Trump campaign pledge. 
Trump criticized high drug prices during the campaign, backing allowing individuals to import them from other countries if they were cheaper. 
He also said in New Hampshire that Medicare could save $300 billion a year on prescription drugs if it negotiated prices. 
"We don't do it," he said. "Why? Because of the drug companies." 
The Cures bill overcame a procedural hurdle on Monday evening, with senators voting 85-13 to end debate. 
The legislation aims to speed up the Food and Drug Administration’s approval of new drugs, while giving new money to medical research.
Liberals argue the bill is a giveaway to pharmaceutical companies without also lowering high drug prices. 
"The debate we are having on this bill is simple, and that is, do we continue to cave in to the demands of the pharmaceutical industry ... or do we have the courage to stand up to the CEO's of big drug companies?" Sanders asked from the floor.